Brief: Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data In Fabry Disease

Sangamo Therapeutics

05/02/2024 23:26

Feb 5 (Reuters) - Sangamo Therapeutics Inc  SGMO.O :
    * SANGAMO THERAPEUTICS ANNOUNCES UPDATED PHASE 1/2 STAAR
STUDY
DATA IN FABRY DISEASE SHOWING SUSTAINED BENEFIT AND
DIFFERENTIATED SAFETY PROFILE
    * SANGAMO THERAPEUTICS INC -CONTINUED FAVORABLE SAFETY
PROFILE,
WITH NO LIVER FUNCTION TEST (LFT) ELEVATIONS REQUIRING STEROIDS
POST-TREATMENT
    * SANGAMO THERAPEUTICS INC -ENROLLMENT IN PHASE 1/2 STAAR
STUDY IS
NOW COMPLETE, WITH DOSING OF REMAINING PATIENTS EXPECTED IN
FIRST HALF OF 2024
    * SANGAMO THERAPEUTICS INC - CONTINUE TO EXPLORE POTENTIAL
PARTNERSHIPS AND OTHER FINANCING OPTIONS TO SUPPORT INITIATION
OF A REGISTRATIONAL TRIAL
    * SANGAMO THERAPEUTICS INC -PRODUCTIVE DISCUSSIONS CONTINUE
WITH
U.S. FDA AND OTHER HEALTH AUTHORITIES ON PATHWAYS TO
REGISTRATION
    * SANGAMO THERAPEUTICS: DEFERRING ADDITIONAL INVESTMENTS IN
PLANNING FOR A REGISTRATIONAL TRIAL UNTIL COLLABORATION
PARTNERSHIP OR FINANCING IS SECURED
    * SANGAMO:ALL 12 PATIENTS WITHDRAWN FROM ERT REMAIN OFF ERT,
WITH
SUSTAINED ELEVATED Α-GAL A ACTIVITY OBSERVED FOR UP TO 19 MTHS
AS OF DATA CUTOFF DATE

Source text for Eikon:  ID:nBw7xXktxa 
Further company coverage:  SGMO.O 

 ((reuters.briefs@thomsonreuters.com;))